Exelixis (EXEL) Cash from Financing Activities (2010 - 2026)

Exelixis (EXEL) recorded quarterly Cash from Financing Activities of -$457.1 million in Q2 2026, down 79.56% quarter-over-quarter from -$254.6 million in Q1 2026, and down 55.05% on a YoY basis from -$1.0 billion in Q2 2025.

Exelixis (EXEL) Cash from Financing Activities (2010 - 2026) Analysis & Trends

Exelixis' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$457.1 million for Q2 2026.

  • In Q2 2026, Cash from Financing Activities fell 55.05% year-over-year to -$457.1 million; the TTM figure through Apr 2026 stood at -$1.1 billion (down 53.04% YoY), while the FY2026 annual figure was -$969.6 million, down 54.2% from the prior year.
  • Cash from Financing Activities was -$457.1 million for Q2 2026 at Exelixis, down from -$254.6 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $5.7 million in Q3 2024 to a low of -$457.1 million in Q2 2026.
  • Historically, Cash from Financing Activities has averaged -$153.0 million across 5 years, with a median of -$184.0 million in 2024.
  • Biggest YoY gain for Cash from Financing Activities was 2137.07% in 2023; the steepest drop was 10678.85% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at -$2.0 million in 2022, then tumbled by 10193.21% to -$206.2 million in 2023, then surged by 102.76% to $5.7 million in 2024, then slumped by 1923.38% to -$103.9 million in 2025, then slumped by 340.12% to -$457.1 million in 2026.
  • The last three Cash from Financing Activities figures came in at -$457.1 million (Q2 2026), -$254.6 million (Q1 2026), and -$103.9 million (Q4 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Alterity Therapeutics 788,338.31 Bn 788,338.28 Bn - -
2 Belite Bio 56,560.00 Bn 56,560.00 Bn - -
3 Quantum Biopharma 17,329.30 Bn 17,329.30 Bn - 7.00 Mn
4 Legend Biotech 3,341.00 Bn 3,340.71 Bn 242.10 Mn -600,000.00
5 Akari Therapeutics 1,727.91 Bn 1,727.91 Bn - 53,000.00
6 Evaxion A 1,536.68 Bn 1,536.67 Bn - -
7 Psyence Biomedical 238.34 Bn 238.33 Bn - -
8 Vertex Pharmaceuticals 113.42 Bn 106.17 Bn 2.59 Bn -538.80 Mn
9 Abivax 95.45 Bn 95.45 Bn - 85,464.43
10 Exelixis 13.71 Bn 12.93 Bn 590.86 Mn -457.11 Mn

Historic Data

Download Data
DateValue
Apr 3, 2026 -457.11 Mn
Apr 3, 2026 -457.11 Mn
Jan 2, 2026 -254.57 Mn
Jan 2, 2026 -254.57 Mn
Oct 3, 2025 -103.86 Mn
Oct 3, 2025 -103.86 Mn
Jul 4, 2025 -316.34 Mn
Jul 4, 2025 -316.34 Mn
Apr 4, 2025 -294.82 Mn
Apr 4, 2025 -294.82 Mn
Jan 3, 2025 -188.03 Mn
Jan 3, 2025 -188.03 Mn
Sep 27, 2024 5.70 Mn
Sep 27, 2024 5.70 Mn
Jun 28, 2024 -262.42 Mn
Jun 28, 2024 -262.42 Mn
Mar 29, 2024 -184.05 Mn
Mar 29, 2024 -184.05 Mn
Dec 29, 2023 -206.17 Mn
Dec 29, 2023 -206.17 Mn